期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

肌氨酰胺亚硝脲药效及药代动力学研究进展

Study Progress of 2-chloroethyl-3-sarcosinamide-1-nitrosourea (SarCNU) about its Pharmacodynamics and Pharmacokinetics
下载PDF
导出
摘要 肌氨酰胺亚硝脲(SarCNU)为亚硝脲类抗癌药,同已在临床使用的亚硝脲类药物相比,该药物具有较高的抗癌活性,同时毒性较低。本文结合国内外相关文献从药效学、药代动力学两个方面对该药物的研究进展进行综述,为SarCNU临床应用和进一步研发提供参考。 2-Chloroethyl-3-sarcosinamide-1-nitrosourea （SarCNU） is an anticancer drug belonging to Nitrosourea,it has higher anti-cancer activity and lower toxicity compared with the other drugs of this kind used in clinic. This article reviews the progresses of this drug about its pharmacodynamics and pharmacokinetics in order to provide reference for the clinical application and further development of SarCNU.
作者 王振波 赵丽娇 钟儒刚
机构地区 北京工业大学生命科学与生物工程学院
出处 《医学综述》 2008年第9期1281-1284,共4页 Medical Recapitulate
基金 国家自然科学基金项目资助(20672011) 北京市自然科学基金项目资助(8072006) 北京市属市管高等学校人才强教计划资助项目
关键词 肌氨酰胺亚硝脲 抗癌药物 药效学 药代动力学 2-Chloroethyl-3-sarcosinamide-1-nitrosourea Anficancer drug Pharmacodynamics Pharmacokinetics
分类号 R979.1 [医药卫生—药品]
  • 相关文献

参考文献15

  • 1Webster M,Caimcross G,Gertler S,et al. Phase Ⅱ trial of SarCNU in malignant glioma: Unexpected pulmonary toxicity with a novel nitrosourea - A phase Ⅱ trial of the national cancer institute of canada clinical trials group[ J]. Invest New Drugs,2005,23(6) :591- 596.
  • 2Wong RP,Baetz T,Krahn MJ,et al. SarCNU in recurrent or metastatic colorectal cancer: A phase Ⅱ study of the National Cancer Institute of Canada Clinical Trials Group[ J ]. Invest New Drugs, 2006,24(4) :347-351.
  • 3Zielske SP, Gerson SL. SarCNU mediates selection of P140K methylguanine-DNA- methyltransferase transduced human CD34^+ cells in vitro[J]. Blood Cells Mol Dis,2003,31 ( 1 ) :48-50.
  • 4Panasci L,Stinson SF, Melnychuk D, et al. SarCNU, a nitrosourea analog on a day 1,5,and 9 oral schedule: A phase Ⅰ and pharmacokinetic study in patients with advanced solid tumors [ J ]. Clin Oncol,2003,21 (2) :232-240.
  • 5Marcantanio D ,Panasci LC, Hollingshead MG et al. 2-Chloroethyl- 3- sarcosinamide-1-nltmsourea, a novel chloroethylnitrosourea analogue with enhanced antitumor activity against human glioma xenografts[J]. Cancer Res, 1997,57(18) :3895-3898.
  • 6Nguyen TH, Ong CK, Wong E, et al. 2-Chloroethyl-3-sarcosinamide-1-nitrosourea (SarCNU) exhibits p53-dependent and p53- independent antiproliferative activity in human nasopharyngeal carcinoma cells in vitro and in vivo [J]. Int J Oncol, 2005,27 (4) : 1131-1140.
  • 7Huynh H, Nguyen TH, Panasci L, et al. 2-Chloroethyl-3-sarcosinamide-1-nitrosourea (SarCNU)inhibits prostate carcinoma cell growth via p53-dependent and p53-independent pathways [ J ]. Cancer,2004,101 (12) :2881-2891.
  • 8Hung HN, Pierce CKH, Chee SK, et al. SarCNU-induced G2/M arrest in hepatoma cells is mediated by a p53-independent phosphorylation of cdc-2 at Tyr15 [ J ]. J Cell Physiol,2005,204 (3) : 785-791.
  • 9Noe AJ,Marcantonio D,Barton J,et al. Characterization of the catecholamine extraneuronal uptake, carrier in human glioma cell lines SK-MG-1 and SKId in relation to (2-chloroethyl)-3-sareosinamide-1-nitrosourea ( SarCNU ) selective cytotoxicity [ J ]. Biochem Pharmacol,1996, 51 (12) :1639-1648.
  • 10潘峻,黄强,兰青,孙志方,王爱东,周丽英,陈忠平,PanasciLC.SarCNU在MGMT耐药基因高表达荷瘤鼠中抗瘤作用分析[J].实用肿瘤杂志,2000,15(3):173-175. 被引量：5

二级参考文献1

  • 1王刚，江苏医药，1998年，24卷，1期，797页

共引文献4

医学综述
2008年 第9期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部